TWI906214B - 脂質體調配物及其使用及製備方法 - Google Patents

脂質體調配物及其使用及製備方法

Info

Publication number
TWI906214B
TWI906214B TW109110461A TW109110461A TWI906214B TW I906214 B TWI906214 B TW I906214B TW 109110461 A TW109110461 A TW 109110461A TW 109110461 A TW109110461 A TW 109110461A TW I906214 B TWI906214 B TW I906214B
Authority
TW
Taiwan
Prior art keywords
salt
mol
composition
moles
peg
Prior art date
Application number
TW109110461A
Other languages
English (en)
Chinese (zh)
Other versions
TW202102231A (zh
Inventor
安格尼斯 拉法爾柯
白倉鐵平
山謬爾 艾瑞克 格林伯格
Original Assignee
美商葛里柯麥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商葛里柯麥公司 filed Critical 美商葛里柯麥公司
Publication of TW202102231A publication Critical patent/TW202102231A/zh
Application granted granted Critical
Publication of TWI906214B publication Critical patent/TWI906214B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109110461A 2019-03-29 2020-03-27 脂質體調配物及其使用及製備方法 TWI906214B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962826874P 2019-03-29 2019-03-29
US62/826,874 2019-03-29

Publications (2)

Publication Number Publication Date
TW202102231A TW202102231A (zh) 2021-01-16
TWI906214B true TWI906214B (zh) 2025-12-01

Family

ID=72666933

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109110461A TWI906214B (zh) 2019-03-29 2020-03-27 脂質體調配物及其使用及製備方法

Country Status (19)

Country Link
US (1) US20220184107A1 (enExample)
EP (1) EP3946365A4 (enExample)
JP (1) JP7583741B2 (enExample)
KR (1) KR20210143906A (enExample)
CN (1) CN113873998A (enExample)
AR (1) AR119705A1 (enExample)
AU (1) AU2020252005B2 (enExample)
BR (1) BR112021019593A2 (enExample)
CA (1) CA3134828A1 (enExample)
CL (1) CL2021002512A1 (enExample)
CO (1) CO2021014274A2 (enExample)
EA (1) EA202192663A1 (enExample)
IL (1) IL286713B2 (enExample)
MX (1) MX2021011876A (enExample)
PE (1) PE20212366A1 (enExample)
PH (1) PH12021552428A1 (enExample)
SG (1) SG11202110623PA (enExample)
TW (1) TWI906214B (enExample)
WO (1) WO2020205530A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205628A1 (en) * 2022-04-18 2023-10-26 City Of Hope Lipid nanoparticles, nucleic acids, and methods of use
TW202543582A (zh) * 2024-02-29 2025-11-16 美商葛里柯麥公司 脂質體調配物及其使用及製備方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110014272A1 (en) * 2009-05-14 2011-01-20 Sanofi Pasteur Method for adjuvanting lipopolysaccharide (LPS) of Gram-negative bacteria
US20160228364A1 (en) * 2013-09-16 2016-08-11 Glycomine, Inc. Pharmaceutical preparation of carbohydrates for therapeutic use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1156783B1 (en) * 1999-03-02 2007-10-24 Transave, Inc. Encapsulation of bioactive complexes in liposomes
US7060291B1 (en) * 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
WO2002076428A1 (en) * 2001-03-26 2002-10-03 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
AU2003205048B2 (en) * 2002-01-09 2009-02-26 Transave, Inc. Efficient liposomal encapsulation
WO2003059322A1 (en) * 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
MX366055B (es) 2011-08-31 2019-06-26 Novartis Ag Liposomas pegilados para admistracion de acido ribonucleico (arn) que codifica para inmunogeno.
CA2890725A1 (en) 2012-11-05 2014-05-08 Pronai Therapeutics, Inc. Methods of using biomarkers for the treatment of cancer by modulation of bcl2|expression
JP2017537650A (ja) 2014-10-09 2017-12-21 ライポテック・ピーティーワイ・リミテッド キメラタンパク質
US20170165374A1 (en) * 2015-11-18 2017-06-15 Insmed, Inc. Compositions and methods for treating bacterial infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110014272A1 (en) * 2009-05-14 2011-01-20 Sanofi Pasteur Method for adjuvanting lipopolysaccharide (LPS) of Gram-negative bacteria
US20160228364A1 (en) * 2013-09-16 2016-08-11 Glycomine, Inc. Pharmaceutical preparation of carbohydrates for therapeutic use

Also Published As

Publication number Publication date
EP3946365A4 (en) 2023-04-19
SG11202110623PA (en) 2021-10-28
CN113873998A (zh) 2021-12-31
AU2020252005A1 (en) 2021-11-04
JP2022527638A (ja) 2022-06-02
MX2021011876A (es) 2022-01-04
AR119705A1 (es) 2022-01-05
CL2021002512A1 (es) 2023-01-06
KR20210143906A (ko) 2021-11-29
AU2020252005B2 (en) 2025-11-27
CA3134828A1 (en) 2020-10-08
EP3946365A1 (en) 2022-02-09
JP7583741B2 (ja) 2024-11-14
EA202192663A1 (ru) 2022-03-01
US20220184107A1 (en) 2022-06-16
WO2020205530A1 (en) 2020-10-08
IL286713A (en) 2021-10-31
IL286713B1 (en) 2025-03-01
PE20212366A1 (es) 2021-12-21
IL286713B2 (en) 2025-07-01
BR112021019593A2 (pt) 2021-12-14
TW202102231A (zh) 2021-01-16
CO2021014274A2 (es) 2022-01-17
PH12021552428A1 (en) 2022-07-11

Similar Documents

Publication Publication Date Title
US12201695B2 (en) Polyglutamated pemetrexed and uses thereof
EP2323693B1 (en) Drug carriers
US20240082155A1 (en) Pharmaceutical preparation of carbohydrates for therapeutic use
TWI906214B (zh) 脂質體調配物及其使用及製備方法
JP6744046B2 (ja) ｃＧＭＰアナログの標的化されたリポソーム送達
WO2007091661A1 (ja) 分子イメージングに適した糖鎖修飾リポソームならびにその利用および製造
EA050120B1 (ru) Липосомальные фармацевтические композиции и способ их применения
TW202600145A (zh) 治療患有先天性醣基化障礙（ｃｄｇ）的個體的先天性醣基化障礙和共濟失調的方法
WO2020061670A1 (pt) Formulação lipossomal, composição farmacêutica, uso de uma formulação lipossomal, método para tratamento de câncer, e, processo para preparação de uma formulação lipossomal
BR122024017509B1 (pt) Composições lipossomais de antifolatos poliglutamatados dglutamil, seu uso e método de preparação